BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24914849)

  • 21. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?
    Dall'Era M; Carroll P
    J Urol; 2015 Sep; 194(3):615-6. PubMed ID: 26079332
    [No Abstract]   [Full Text] [Related]  

  • 22. Designing Normative Messages About Active Surveillance for Men With Localized Prostate Cancer.
    Volk RJ; Kinsman GT; Le YC; Swank P; Blumenthal-Barby J; McFall SL; Byrd TL; Mullen PD; Cantor SB
    J Health Commun; 2015; 20(9):1014-20. PubMed ID: 26066011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
    Reese AC; Landis P; Han M; Epstein JI; Carter HB
    J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Selection criteria and nomograms for active surveillance in prostate cáncer].
    Borque A; Esteban LM; Sanz G; Rubio-Briones J; Gil MJ
    Arch Esp Urol; 2014 Jun; 67(5):419-30. PubMed ID: 24914841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Economic features of active surveillance].
    Huguet J; Musquera M; Ribal MJ; Alcaraz A
    Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active surveillance in low-risk prostate cancer. Patient acceptance and results.
    Hernández V; Blázquez C; de la Peña E; Pérez-Fernández E; Díaz FJ; Llorente C
    Actas Urol Esp; 2013 Oct; 37(9):533-7. PubMed ID: 23618513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active surveillance for clinically localized prostate cancer--a systematic review.
    Thomsen FB; Brasso K; Klotz LH; Røder MA; Berg KD; Iversen P
    J Surg Oncol; 2014 Jun; 109(8):830-5. PubMed ID: 24610744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    Eur Urol; 2009 Jan; 55(1):1-8. PubMed ID: 18805628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pros and cons of active surveillance for low-risk prostate cancer].
    Chiba K; Akakura K
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2538-41. PubMed ID: 22189217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Results of active surveillance in low and intermediate risk prostate cancer].
    Llorente C; Diaz Goizueta FJ; Hernandez V; de la Morena JM; de la Peña E
    Arch Esp Urol; 2014 Jun; 67(5):452-6. PubMed ID: 24914844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Active surveillance of prostatic cancer].
    Vasarainen H; Ruutu M; Rannikko A
    Duodecim; 2011; 127(6):593-9. PubMed ID: 21528523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer.
    Davison BJ; Goldenberg SL
    BJU Int; 2011 Dec; 108(11):1787-93. PubMed ID: 21507187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychological aspects of active surveillance.
    van den Bergh RC; Korfage IJ; Bangma CH
    Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expectant management for men with early stage prostate cancer.
    Filson CP; Marks LS; Litwin MS
    CA Cancer J Clin; 2015; 65(4):265-82. PubMed ID: 25958817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment options for localized prostate cancer.
    Mohan R; Schellhammer PF
    Am Fam Physician; 2011 Aug; 84(4):413-20. PubMed ID: 21842788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economics of active surveillance for prostate cancer.
    Dall'Era MA
    Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.